StockNews.com Initiates Coverage on Tonix Pharmaceuticals (NASDAQ:TNXP)

Equities researchers at StockNews.com began coverage on shares of Tonix Pharmaceuticals (NASDAQ:TNXP) in a report released on Monday. The firm set a “hold” rating on the stock.

Tonix Pharmaceuticals Price Performance

TNXP stock opened at $0.39 on Monday. The stock has a market cap of $72.01 million, a price-to-earnings ratio of -0.01 and a beta of 2.23. Tonix Pharmaceuticals has a fifty-two week low of $0.12 and a fifty-two week high of $14.08. The company has a quick ratio of 2.81, a current ratio of 3.33 and a debt-to-equity ratio of 0.07. The business has a 50 day moving average price of $0.21 and a 200 day moving average price of $0.41.

Tonix Pharmaceuticals (NASDAQ:TNXP) last issued its earnings results on Tuesday, November 12th. The company reported ($0.23) earnings per share (EPS) for the quarter, beating the consensus estimate of ($2.03) by $1.80. Tonix Pharmaceuticals had a negative net margin of 1,197.86% and a negative return on equity of 163.95%. The business had revenue of $2.82 million during the quarter, compared to analysts’ expectations of $2.63 million. Equities research analysts anticipate that Tonix Pharmaceuticals will post -17.63 earnings per share for the current fiscal year.

About Tonix Pharmaceuticals

Tonix Pharmaceuticals Holding Corp., a biopharmaceutical company, focuses on developing, discovering, commercializing, and licensing therapeutics to treat and prevent human disease and alleviate suffering. It markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults.